




CHOOSE
KISQALI 1ST
GIVING MORE LIFE
TO WOMEN
WITH HR+/HER2- ABC



“DOCTOR, HOW LONG WILL I HAVE TO LIVE?”


ISN'T THAT THE QUESTION EVERY PATIENT WITH ADVANCED OR METASTATIC **HR+/HER2-** BREAST CANCER IS ASKING YOU?

NOW **WITH KISQALI** YOU CAN ANSWER THIS **WITH CONFIDENCE!**




KISQALI-THE LONGEST MEDIAN OVERALL SURVIVAL
EVER REPORTED IN HR+/HER2- ABC

THE ONLY CDK4/6 INHIBITOR WITH STATISTICALLY SIGNIFICANT OVERALL SURVIVAL PROVEN ACROSS ALL 3 PHASE III TRIALS



MONALEESA-2: POSTMENOPAUSAL PATIENTS WITH AI
THE LONGEST MEDIAN OVERALL SURVIVAL EVER
REPORTED IN HR+/HER2- ABC

MONALEESA-2: KISQALI + AI IN POSTMENOPAUSAL PATIENTS
AT A MEDIAN FOLLOW-UP OF 80 MONTHS



* mPFS: Statistical significance was established in the prespecified interim analysis (HR=0.56 [95% CI: 0.43-0.72]; P<0.0001). In the updated analysis, mPFS was 25.3 months for KISQALI + letrozole vs 16.0 months with placebo + letrozole (HR=0.57 [95% CI: 0.46-0.70]; P<0.0001)^{4,5}
Hazard ratios are based on stratified Cox model.



NOW KISQALI GIVES PATIENTS MORE LIFE
WITH CONFIDENCE!



Abbreviations:
CI, confidence interval; HR, hazard ratio; LET, letrozole; mOS, median overall survival; mPFS, median progression-free survival; AI, aromatase inhibitor; PBO, Placebo; ET, endocrine therapy; mo, month.

References:
1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with endocrine therapy ± ribociclib. Presented at: European Society of Medical Oncology; September 16-21, 2021. 2. Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2020; San Antonio, TX. Poster PD2-04. 3. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021 Aug;32(8):1015-1024. 4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748. 5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-1547.

DO YOU FIND THESE INFORMATION VALUABLE?



National Succinct Statement (NSS)

Patient Safety Team Contact Details